An intermittent fasting regimen reduced liver fat buildup and lowered the likelihood of liver cancer in mouse models of metabolic dysfunction-associated steatohepatitis (MASH), a severe…
Reduced activity of a protein called GPR75 appears to help prevent the buildup of fat in the liver and the subsequent development of metabolic dysfunction-associated…
The U.S. government soon will launch a first national study to assess the prevalence of metabolic dysfunction-associated steatotic liver disease, or MASLD — a liver…
FXR314, an investigational oral therapy, safely and effectively reduced liver fat content in adults with a severe form of fatty liver disease called metabolic…
The approval of Rezdiffra (resmetirom) last month in the U.S. as the first ever treatment for nonalcoholic steatohepatitis (NASH), a severe type of…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to DD01 as a potential treatment for a severe manifestation of fatty…
Chiglitazar (carfloglitazar), an oral medication approved to treat type 2 diabetes in China, led to significant reductions in liver fat accumulation among people with nonalcoholic…
Inventiva’s investigational oral therapy lanifibranor safely reduced blood sugar levels and eased signs of liver disease among people with metabolic dysfunction-associated steatohepatitis (MASH), a…
A possible therapeutic target for fatty liver disease (FLD) has been identified by researchers studying the natural defense mechanisms of certain cave-dwelling fish. While…
The U.S. Food and Drug Administration (FDA) has approved Rezdiffra (resmetirom) for the treatment of people with noncirrhotic nonalcoholic steatohepatitis (NASH) — a severe type…
